Type 1 Diabetes Management Beyond Insulin: Aligning Evidence, Research, and Regulation [0.03%]
超越胰岛素的1型糖尿病管理：协调证据、研究和监管
Courtney A Ackeifi,Viral N Shah
Courtney A Ackeifi
The Horizon Ahead: Emerging Adjunctive Therapies for Type 1 Diabetes [0.03%]
展望 horizon ahead：1 型糖尿病的新兴辅助疗法
Vala Hamidi,Jeremy H Pettus
Vala Hamidi
This perspective outlines a clinical roadmap for integrating adjunctive metabolic therapies into the care of people with type 1 diabetes. Despite major advances in insulin delivery and technology, cardiometabolic risk, weight gain, and glyc...
Expectations and Experiences: What People with Type 1 Diabetes Really Want from Adjunctive Therapies [0.03%]
期望与体验：1型糖尿病患者真正希望从辅助治疗中获得什么
Julie Keller Heverly
Julie Keller Heverly
This article of existing research and insights from individuals with type 1 diabetes (T1D) combines the results of surveys, interviews, clinical note reviews, and personal expectations and experiences to demonstrate what is still needed and...
Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents [0.03%]
GLP-1受体激动剂与SGLT2抑制剂联用治疗1型糖尿病：为什么、何时及如何使用？兼论这两种辅助用药联合应用的原理和临床场景探讨
Husam Ghanim,Sambasiva Rao Srungavarapu,Paresh Dandona et al.
Husam Ghanim et al.
Even with the most advanced insulin preparations and delivery systems currently available, it is challenging for many people with type 1 diabetes (T1D) to achieve target levels of glycemic management. Adjunct therapy in T1D consists of addi...
Clinical Guidance on the Safe Use of Sodium-Glucose Cotransporter Inhibitors in Adults with Type 1 Diabetes [0.03%]
成人1型糖尿病患者使用钠-葡萄糖共转运蛋白抑制剂的临床指导意见
Jayachidambaram Ambalavanan,Kanchan Bhasin,Viral N Shah
Jayachidambaram Ambalavanan
Sodium-glucose cotransporter inhibitors (SGLTi) as an adjunctive to insulin therapy may offer cardiometabolic and renal benefits in adults with type 1 diabetes (T1D). Their effective use depends on patient selection, education, and ketone m...
Clinical Guidance on the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in Adults with Type 1 Diabetes [0.03%]
成人1型糖尿病患者使用胰高血糖素样肽-1受体激动剂的安全性专家指导建议
Zeb I Saeed,Viral N Shah
Zeb I Saeed
This article provides a stepwise guidance on the safe use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as adjunctive therapy in adults with type 1 diabetes (T1D). Here, we first identify the phenotypes within T1D most likely to b...
Future of Continuous Ketone Monitoring and Its Utility for Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes [0.03%]
连续监测酮体的未来及其在1型糖尿病患者中安全使用钠-葡萄糖共转运蛋白2抑制剂中的作用
Halis K Akturk
Halis K Akturk
Continuous ketone monitoring (CKM) may address the principal barrier to adjunctive sodium-glucose cotransporter-2 inhibitor use in type 1 diabetes: Unrecognized ketosis and euglycemic diabetic ketoacidosis. Unlike conventional urine or capi...
Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes [0.03%]
用于1型糖尿病肾脏保护的钠-葡萄糖共转运蛋白抑制剂、肠促胰素受体激动剂（胰高血糖素样肽-1受体激动剂和双作用葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1受体激动剂）以及芬瑞诺酮
Michael S Hughes,Francisco J Pasquel
Michael S Hughes
Diabetes-related kidney disease (DKD) is a major complication of type 1 diabetes (T1D) and remains a leading cause of kidney failure and cardiovascular risk. In this article, we summarize the biologic rationale and emerging clinical evidenc...
Emerging Evidence for Cardiorenal Protection with Sodium-Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes [0.03%]
用于1型糖尿病患者的钠-葡萄糖共转运蛋白抑制剂、胰高血糖素样肽-1受体激动剂和盐皮质激素受体阻滞剂的心肾保护作用的新证据
Stuti Fernandes,Barbara Hettinger,Lynn Ang et al.
Stuti Fernandes et al.
Sodium-glucose cotransporter inhibitors, glucagon-like peptide 1 receptor agonists and mineralocorticoid receptor blockers have revolutionized type 2 diabetes and by providing substantial cardiovascular and renal protection in this. This ar...